For example, an anti-ICAM-1 monoclonal antibody (R6.5, enlimomab) was tested in clinical trials in patients with rheumatoid arthritis, acute stroke, and to treat acute rejection of renal transplants and burn injury32–35. The gene discussed is ICAM1; the disease is rheumatoid arthritis.